Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Darryle D Schoepp

Showing results (11-20 of 40) with videos related to

Pageof 4
Sort By:
Molecular Interventions|April 12, 2008
Schizophrenia: moving beyond monoamine antagonistsP Jeffrey Conn, Carol Tamminga, Darryle D Schoepp, et al.
Neuropharmacology|May 31, 2006
Effects of mGlu2 or mGlu3 receptor deletions on mGlu2/3 receptor agonist (LY354740)-induced brain c-Fos expression: specific roles for mGlu2 in the amygdala and subcortical nuclei, and mGlu3 in the hippocampusAnni-Maija Linden, Melvin Baez, Marcelle Bergeron, et al.
CNS & Neurological Disorders Drug Targets|April 14, 2007
Metabotropic glutamate receptors in the control of mood disordersJeffrey M Witkin, Gerard J Marek, Bryan G Johnson, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 22, 2008
Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039)Matthew J Fell, Kjell A Svensson, Bryan G Johnson, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 23, 2007
Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorderEduardo Dunayevich, Janelle Erickson, Louise Levine, et al.
Pharmacology, Biochemistry, and Behavior|July 16, 2002
Effects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine-sensitized ratsMatthew Clark, Bryan G Johnson, Rebecca A Wright, et al.
Stress (Amsterdam, Netherlands)|September 18, 2003
LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stressDarryle D Schoepp, Rebecca A Wright, Louise R Levine, et al.
Nature Reviews. Drug Discovery|January 25, 2005
Metabotropic glutamate receptors as novel targets for anxiety and stress disordersChad J Swanson, Mark Bures, Michael P Johnson, et al.
Nuclear Medicine and Biology|March 8, 2003
Evaluation of [3H]LY341495 for labeling group II metabotropic glutamate receptors in vivoRikki N Waterhouse, Mark E Schmidt, Abida Sultana, et al.
Bioorganic & Medicinal Chemistry Letters|December 18, 2004
(2S,1'S,2'R,3'R)-2(2'-Carboxy-3'-hydroxymethylcyclopropyl)glycine-[3H], a potent and selective radioligand for labeling group 2 and 3 metabotropic glutamate receptorsWilliam J Wheeler, Dean K Clodfelter, Ivan Collado, et al.
Pageof 4

Showing results (11-20 of 40) with videos related to

Sort By:
Pageof 4
Molecular Interventions|April 12, 2008
Schizophrenia: moving beyond monoamine antagonistsP Jeffrey Conn, Carol Tamminga, Darryle D Schoepp, et al.
Neuropharmacology|May 31, 2006
Effects of mGlu2 or mGlu3 receptor deletions on mGlu2/3 receptor agonist (LY354740)-induced brain c-Fos expression: specific roles for mGlu2 in the amygdala and subcortical nuclei, and mGlu3 in the hippocampusAnni-Maija Linden, Melvin Baez, Marcelle Bergeron, et al.
CNS & Neurological Disorders Drug Targets|April 14, 2007
Metabotropic glutamate receptors in the control of mood disordersJeffrey M Witkin, Gerard J Marek, Bryan G Johnson, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 22, 2008
Evidence for the role of metabotropic glutamate (mGlu)2 not mGlu3 receptors in the preclinical antipsychotic pharmacology of the mGlu2/3 receptor agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]hexane-4,6-dicarboxylic acid (LY404039)Matthew J Fell, Kjell A Svensson, Bryan G Johnson, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|August 23, 2007
Efficacy and tolerability of an mGlu2/3 agonist in the treatment of generalized anxiety disorderEduardo Dunayevich, Janelle Erickson, Louise Levine, et al.
Pharmacology, Biochemistry, and Behavior|July 16, 2002
Effects of the mGlu2/3 receptor agonist LY379268 on motor activity in phencyclidine-sensitized ratsMatthew Clark, Bryan G Johnson, Rebecca A Wright, et al.
Stress (Amsterdam, Netherlands)|September 18, 2003
LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stressDarryle D Schoepp, Rebecca A Wright, Louise R Levine, et al.
Nature Reviews. Drug Discovery|January 25, 2005
Metabotropic glutamate receptors as novel targets for anxiety and stress disordersChad J Swanson, Mark Bures, Michael P Johnson, et al.
Nuclear Medicine and Biology|March 8, 2003
Evaluation of [3H]LY341495 for labeling group II metabotropic glutamate receptors in vivoRikki N Waterhouse, Mark E Schmidt, Abida Sultana, et al.
Bioorganic & Medicinal Chemistry Letters|December 18, 2004
(2S,1'S,2'R,3'R)-2(2'-Carboxy-3'-hydroxymethylcyclopropyl)glycine-[3H], a potent and selective radioligand for labeling group 2 and 3 metabotropic glutamate receptorsWilliam J Wheeler, Dean K Clodfelter, Ivan Collado, et al.
Pageof 4